FDA Asks for Input on Reporting Pet Drug Side Effects
Published Date: 2/20/2026
Notice
Summary
The FDA wants your thoughts on how it collects reports about problems with new animal drugs and manufacturing issues. This affects drug makers, vets, and pet owners who help spot side effects in animals. Comments are open until April 21, 2026, so jump in now to help shape safer animal medicines without adding extra costs or delays.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Animal-drug makers: large reporting burden
If you are an applicant or other maker of approved new animal drugs, you must keep records and submit postmarketing adverse event and manufacturing-defect reports under section 512(l) of the FD&C Act and 21 CFR 514.80. FDA lists required forms (FDA Form 1932 and 2301), requires electronic submission of postmarketing safety reports (with limited temporary waivers), and estimates total annual reporting of about 139,561 responses and 194,349.5 hours and total annual recordkeeping of about 124,443 records and 1,742,132 hours (OMB Control Number 0910-0284).
Vets and pet owners: voluntary adverse-event reports
Veterinarians and pet owners can voluntarily report animal adverse events to FDA using FDA Form 1932a; FDA estimates about 217 voluntary public reports per year totaling about 217 hours. These voluntary reports help FDA monitor safety of new animal drugs.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2026-03351, Development of Guidance for Alternative Fuel Vehicles and Fueling Infrastructure Deployment Under the Clean School Bus Funding Programs
The EPA is gearing up to launch a new funding program to help schools switch to cleaner, alternative fuel buses and build the needed fueling stations. They want your input by April 6, 2026, to make sure the program covers all clean bus technologies and protects taxpayer money from waste or fraud. This means more choices and stronger rules for school districts ready to go green soon!
Next: 2026-03353, Agency Information Collection Activities; Proposed Collection; Comment Request; New Animal Drugs for Minor Use and Minor Species
The FDA wants your thoughts on how they collect info about new animal drugs for less common animals and uses. This helps make sure these drugs are safe and effective without causing extra paperwork headaches. If you’re involved with these drugs, you’ve got until April 21, 2026, to share your comments—no cost, just your voice!